OncoMatch/Clinical Trials/NCT05080010
Adjuvant Chemotherapy for High-risk Postenucleation Retinoblastoma
Is NCT05080010 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies 3 cycles chemotherapy for retinoblastoma.
Treatment: 3 cycles chemotherapy — The purpose of this study is to determine the effect of 3 cycles of chemotherapy(CEV) in the treatment of Stage I enucleated retinoblastoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Disease stage
Required: Stage I
Prior therapy
Must have received: enucleation — study eye
Received enucleation in the study eye
Cannot have received: chemical intervention
History of chemical intervention for retinoblastoma in the study eye
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05080010 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior chemical intervention disqualifies patients from enrollment.
What disease stage is eligible?
Stage I is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify